Kalaris Therapeutics, Inc. SEC filings KLRS
Kalaris Therapeutics, Inc. has 699 filings in SEC EDGAR's recent list, going back to Oct 2, 2018. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 24, 2026 | — |
| DEF 14A | Proxy statement | Apr 24, 2026 | Jun 3, 2026 |
| DEFA14A | Additional proxy material | Jul 1, 2025 | — |
| DEF 14A | Proxy statement | Jul 1, 2025 | Aug 12, 2025 |
| DEF 14A | Proxy statement | Dec 6, 2024 | Jan 9, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 26, 2024 | Nov 26, 2024 |
| DEFA14A | Additional proxy material | Apr 23, 2024 | — |
| DEF 14A | Proxy statement | Apr 23, 2024 | Jun 6, 2024 |
| DEFA14A | Additional proxy material | Mar 31, 2023 | — |
| DEF 14A | Proxy statement | Mar 31, 2023 | May 11, 2023 |
| PRE 14A | Preliminary proxy statement | Mar 21, 2023 | May 11, 2023 |
| DEFA14A | Additional proxy material | Apr 6, 2022 | — |
| DEF 14A | Proxy statement | Apr 6, 2022 | May 17, 2022 |
| DEFA14A | Additional proxy material | Apr 12, 2021 | — |
| DEF 14A | Proxy statement | Apr 12, 2021 | May 25, 2021 |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- KLRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Berkeley Heights, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1754068
- Former names
- Allovir, Inc. (until Mar 12, 2025); ViraCyte, Inc. (until Oct 2, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.